Skip to main content
Premium Trial:

Request an Annual Quote

Buoyed by CAT Payment, Stratagene Says Q4 Revenue Surged 153 Percent; Profit Grew 18 Percent

NEW YORK, March 8 (GenomeWeb News) - Stratagene yesterday reported a 153-percent surge in revenues and an 18-percent increase in profit for the fourth quarter.


Stratagene's revenues for the three months ended Dec.31, 2005, jumped to $57.1 million from $22.6 million year over year. The company said that driving the results was a one-time receipt of $34.1 million from Cambridge Antibody Technology as part of Abbott Laboratories' Humira drug developemt.


Excluding this one-time revenue item, Stratagene said that fourth-quarter revenue increased 2.1 percent to $23 million.


R&D expenses increased 43 percent to $3.9 million for the fourth quarter from $2.7 million for the same period in 2004, Stratagene said. It attributed the rise to additional investments in the development of biology-focused pathway-analysis software.


The company's net income grew to $2 million from $1.7 million in the year-ago period.


Stratagene had approximately $35 million in cash and cash equivalents as of Dec. 31.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.